Roivant Sciences Ltd. (ROIV): Price and Financial Metrics
ROIV Price/Volume Stats
| Current price | $12.55 | 52-week high | $13.24 |
| Prev. close | $13.19 | 52-week low | $3.14 |
| Day low | $12.25 | Volume | 8,332,795 |
| Day high | $13.24 | Avg. volume | 3,978,909 |
| 50-day MA | $11.33 | Dividend yield | N/A |
| 200-day MA | $9.34 | Market Cap | 9.69B |
ROIV Stock Price Chart Interactive Chart >
ROIV POWR Grades
- ROIV scores best on the Sentiment dimension, with a Sentiment rank ahead of 93.66% of US stocks.
- ROIV's strongest trending metric is Value; it's been moving up over the last 177 days.
- ROIV ranks lowest in Quality; there it ranks in the 10th percentile.
ROIV Stock Summary
- ROIV's went public 2.97 years ago, making it older than only 12.34% of listed US stocks we're tracking.
- ROIV's price/sales ratio is 101.45; that's higher than the P/S ratio of 97.84% of US stocks.
- As for revenue growth, note that ROIV's revenue has grown 51.5% over the past 12 months; that beats the revenue growth of 89.67% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to ROIVANT SCIENCES LTD, a group of peers worth examining would be AKTS, CYN, LQDA, PSNL, and SDGR.
- To check out ROIVANT SCIENCES LTD's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001635088.
ROIV Valuation Summary
- In comparison to the median Healthcare stock, ROIV's EV/EBIT ratio is 165.52% lower, now standing at -7.6.
- Over the past 36 months, ROIV's price/earnings ratio has gone down 8.7.
Below are key valuation metrics over time for ROIV.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ROIV | 2023-09-22 | 101.4 | 8.8 | -8.2 | -7.6 |
| ROIV | 2023-09-21 | 100.4 | 8.7 | -8.1 | -7.5 |
| ROIV | 2023-09-20 | 101.4 | 8.8 | -8.2 | -7.6 |
| ROIV | 2023-09-19 | 106.1 | 9.2 | -8.6 | -8.0 |
| ROIV | 2023-09-18 | 109.2 | 9.4 | -8.9 | -8.2 |
| ROIV | 2023-09-15 | 110.9 | 9.6 | -9.0 | -8.4 |
ROIV's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ROIV has a Quality Grade of C, ranking ahead of 35.69% of graded US stocks.
- ROIV's asset turnover comes in at 0.115 -- ranking 251st of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ROIV's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-03-31 | 0.115 | 0.914 | -3.951 |
Roivant Sciences Ltd. (ROIV) Company Bio
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest ROIV News From Around the Web
Below are the latest news stories about ROIVANT SCIENCES LTD that investors may wish to consider to help them evaluate ROIV as an investment opportunity.
The Brash Strategy That Made Vivek Ramaswamy a FortuneGOP presidential hopeful brought the same swagger to his business career as he has to his Republican primary campaign. |
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding WarrantsBASEL, Switzerland and LONDON and NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously announced redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”). The Redemption Fair Market Value will be used to determine the number of Roivant common shares (the “ |
What You Need To Know About The Roivant Sciences Ltd. (NASDAQ:ROIV) Analyst Downgrade TodayThe analysts covering Roivant Sciences Ltd. ( NASDAQ:ROIV ) delivered a dose of negativity to shareholders today, by... |
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business UpdateRVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all dosesFirst patient has been dosed in the TAHOE study, a global Phase 2 trial of RVT-3101 in Crohn’s disease, with topline data from the induction portion expected in the fourth quarter of calendar year 2024Initial data from the Phase 1 clinical trial of IMVT-1402 remains on track for September |
3 Biotech Stocks That Analysts Are Drooling OverWith the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time. |
ROIV Price Returns
| 1-mo | 11.56% |
| 3-mo | 24.50% |
| 6-mo | 70.05% |
| 1-year | 276.88% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 57.07% |
| 2022 | -20.73% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...